

# AEGROS

## DISRUPTING THE US\$20B PLASMA FRACTIONATION INDUSTRY

*Lead Manager: STK Markets*



### Highlights

- There is an increasing need for plasma protein therapies
- Until now the US\$20B global blood & plasma industry has been dominated by CSL, Grifols & Takeda. They still use 1940s technology and have little incentive to improve processes
- COGS represent 57% of plasma industry production costs compared to the pharmaceutical industry standard of 15%
- Only 1 in 4 countries have a domestic fractionation capability
  - most would if an economically viable method was available
- **Aegros's Haemafrac® technology & process is the breakthrough** that enables this. It will disrupt the fractionation industry
- The Haemafrac® produces **higher yields, from smaller batch sizes, faster and at a fraction of the cost** of competitors
- Aegros has **already obtained TGA GMP approval in Australia** for its Macquarie Park plant and for **the manufacture of clinical trial pharmaceuticals**
- **Aegros has already secured 100,000 litres of plasma p.a for 3 years**
- **Signed a JV agreement to build a 1m litre Haemafrac® facility in Singapore, & plasma collection, and pack & fill facilities in Cambodia.**
- With the trial for its first product - a Hyperimmune against Covid19 - successfully concluding, application for TGA approval is imminent
- Aegros has a B2G (Business to Govt.) client model with hundreds of millions revenue potential:
  - Selling products from its 100k & 1m litre Australian & Singapore facilities;
  - Setting up licensed plasma fractionating plants globally;
    - Countries will pay to install & licence use of the Haemafrac®
    - Countries will also pay a % royalty on their production revenue
    - Aegros has already received requests to install & license the Haemafrac® in a number of countries; and
    - Planning with SE Asian & Middle Eastern countries are well advanced
- QLD Government approved Government support Aegros 1 million litre facility
- It is undertaking a **\$10m raising at \$18.00 p/s prior to anticipated TGA approval for its Hyperimmune against Covid19 & valuation re-rate**
- Funds will be used to:
  - Purchase equipment to scale-up the Sydney Plant to a processing capacity of 100,000 litres of plasma pa; and
  - Provide further working capital

## CONTACT

Sean Sandilands

0412 166 471

sean@stkmarkets.com



## RAISE DETAILS

Amount	\$10m
Issue Price	\$18.00 per share
<b>Closing Date</b>	<b>22 Dec. 2023</b>
IPO objective	H2 2024
Fully Diluted Valuation	\$1.28b

**On 1 December Aegros announced Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune. Data is being prepared for submission to the Australian TGA to assess the product for registration.**



**Aegros's HaemaFrac® machine**


# HAEMAFRAC® INDUSTRY DISRUPTION

## HaemaFrac® technology breakthrough

Conventional Plasma Fractionation process




Plasma Fractionation using HaemaFrac®



- Haemafrac® is a scalable membrane-based tangential flow preparative electrophoresis process providing a 1-capture step alternative to the multiple-step ethanol based plasma fractionation Technologies.
- Haemafrac® represents a **single-step, higher yield, higher purity, lower carbon system** that can isolate plasma proteins in their native state and remove viruses in the same process.
- This is a **leap forward for the industry.**

## Higher yields at fraction of cost

- To date the US\$20B blood & plasma industry has been dominated by CSL, Grifols & Takeda- using 1940s technology.
- COGS in the plasma industry are 57% vs 15% general pharma.
- Aegros has developed the Haemafrac® machine & process which **will disrupt the industry.**
- It produces **higher yields, from smaller batch sizes,** and is **significantly faster.**
- **Significantly it reduces COGS** - with **double the yield countries can now establish** a domestic fractionation industry.
- Hundreds of millions in B2G (Bus. to Govt.) revenue potential from:
  - **Manufacture & sale of Aegros produced blood & plasma products**
  - **Sale of turnkey fractionating plants and single use consumables** for use in Aegros' Haemafrac® machines.
- Already demand and orders from state & foreign governments.



## Improving lives globally

	Current producers	Aegros' HaemaFrac®
1m litre plant construction capex	> US\$1b	US\$400m
Plasma required to run a batch	5,000- 10,000 litres	10 litres
Doses produced per litre	2	4
Process steps	Up to 30	One
Time to first treatment	Weeks	Hours
Viral & prion removal capability	No	Yes
Product safety	Lower	Higher
Environmental Impact	Higher	Lower
Bespoke product run ability	Extremely limited	High

Only 55 countries have a domestic plasma-fractionating industry:

- **If it were economically viable most would.**
- WHO resolution 63.12 urges Member States to establish sustainable blood & plasma programmes to achieve self-sufficiency.
- Most countries are reliant on foreign supply and have little price control.
- Raw plasma has become even harder for suppliers to source.
- Haemafrac® provides with **higher purity, less environmental impact, flexibility in product outputs from faster production times** and from **smaller batch sizes.**

**The Aegros HaemaFrac® will save lives and improve people's health globally. This is breakthrough the world has been waiting for.**

## Disclaimer and important information

This information summary has been prepared for Professional and Sophisticated (s708) clients of STK Markets. This information has been prepared in good faith, as a summary only, and does not contain all information about the Aegros offer nor its assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to Aegros securities. The securities to be issued by Aegros are to be considered speculative and there is no guarantee that they will make a return on the capital invested, that dividends will be paid on the shares or that there will be an increase in the value of the shares in the future or that they will list on a recognised exchange. STK Markets or Aegros do not purport to give financial or investment advice. No account has been taken of the objectives, financial situation or needs of any recipient of this presentation. Certain information in this document has been derived from third parties and although STK Markets has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified. Recipients of this presentation should only read it in conjunction with the Information Memorandum provided and carefully consider whether the securities issued by Aegros are an appropriate investment for them in light of their personal circumstances, including their financial and taxation position. Investors should make and rely upon their own enquiries before deciding to acquire or deal in the Company's securities. To the extent permitted by law, STK Markets and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and whether or not arising out of the negligence, default or lack of care of Aegros, STK Markets and/ or any of its Agents) for any loss or damage suffered by a recipient or other persons arising out of, or in connection with, any use or reliance on this presentation or information.